Literature DB >> 3030524

L-648,051, sodium 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)- propylsulfonyl]-gamma-oxo-benzenebutanoate: a leukotriene D4 receptor antagonist.

T R Jones, Y Guindon, R Young, E Champion, L Charette, D Denis, D Ethier, R Hamel, A W Ford-Hutchinson, R Fortin.   

Abstract

L-648,051, sodium 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy) propylsulfonyl]-gamma-oxo-benzenebutanoate is a selective and competitive inhibitor of [3H]leukotriene D4 (KB value of 4.0 microM) and to a lesser extent [3H]leukotriene C4 (Ki value of 36.7 microM) binding in guinea pig lung homogenates. Functionally, it selectively antagonized contractions of guinea pig trachea induced by leukotrienes C4, D4, E4, and F4 in concentrations that did not antagonize contractions induced by acetylcholine, histamine, serotonin, prostaglandin F2 alpha, or U-44069 (endoperoxide analogue). Schild plot analysis indicated that L-648,051 competitively antagonized contractions of guinea pig ileum induced by leukotriene D4 (pA2 7.7) and contractions of trachea induced by leukotrienes D4, E4, and F4 (pA2 7.3, 7.4, and 7.5, respectively). Contractions of guinea pig trachea induced by leukotriene C4 were inhibited in a noncompetitive fashion (Schild plot slope, 0.45). Developed contractions of trachea induced by the leukotrienes were rapidly reversed by L-648,051 greater than FPL-55712 greater than L-649,923. Intravenous L-648,051 selectively blocked bronchoconstriction induced in anaesthetized guinea pigs by intravenous leukotrienes C4, D4, and E4 but not that induced by arachidonic acid, serotonin, U-44069, or acetylcholine. The compound displayed poor activity following intraduodenal administration. The profile of activity for L-648,051 indicates that it may be a useful topical agent for studying the role of leukotrienes in diseases such as bronchial asthma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3030524     DOI: 10.1139/y86-258

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  8 in total

1.  Evidence indicating that leukotrienes C4, D4 and E4 are major mediators of contraction induced by anti-IgE in human bronchi.

Authors:  T Björck; S E Dahlén
Journal:  Agents Actions       Date:  1989-01

2.  Antigen-induced contraction of guinea-pig isolated trachea: studies with novel inhibitors and antagonists of arachidonic acid metabolites.

Authors:  T R Jones; L Charette; D Denis
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

3.  Tolerability and pharmacokinetics of L-648,051. A leukotriene D4-receptor antagonist, in healthy volunteers.

Authors:  J Biollaz; E Stahl; J Y Hsieh; L Distlerath; A Jaeger; P Leuenberger; J L Schelling
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 4.  Leukotriene antagonists and inhibitors as modulators of IgE-mediated reactions.

Authors:  A W Ford-Hutchinson
Journal:  Springer Semin Immunopathol       Date:  1993

5.  Antagonism of leukotriene receptors and administration of a 5-lipoxygenase inhibitor do not affect hypoxic vasoconstriction.

Authors:  H M Thomas; M S Sourour; D Lopez; S H Foster
Journal:  Lung       Date:  1989       Impact factor: 2.584

Review 6.  Regulation of leukotriene biosynthesis.

Authors:  A W Ford-Hutchinson
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

7.  L-648,051, a novel cysteinyl-leukotriene antagonist is active by the inhaled route in man.

Authors:  J M Evans; N C Barnes; J T Zakrzewski; D G Sciberras; E G Stahl; P J Piper; J F Costello
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

8.  Effects of L-serine borate on antagonism of leukotriene C4-induced contractions of guinea-pig trachea.

Authors:  L Charette; T R Jones
Journal:  Br J Pharmacol       Date:  1987-05       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.